These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 31244598)

  • 1. Cerebral Dopamine Neurotrophic Factor Diffuses Around the Brainstem and Does Not Undergo Anterograde Transport After Injection to the Substantia Nigra.
    Albert K; Renko JM; Mätlik K; Airavaara M; Voutilainen MH
    Front Neurosci; 2019; 13():590. PubMed ID: 31244598
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel neurotrophic factor CDNF protects and rescues midbrain dopamine neurons in vivo.
    Lindholm P; Voutilainen MH; Laurén J; Peränen J; Leppänen VM; Andressoo JO; Lindahl M; Janhunen S; Kalkkinen N; Timmusk T; Tuominen RK; Saarma M
    Nature; 2007 Jul; 448(7149):73-7. PubMed ID: 17611540
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chronic infusion of CDNF prevents 6-OHDA-induced deficits in a rat model of Parkinson's disease.
    Voutilainen MH; Bäck S; Peränen J; Lindholm P; Raasmaja A; Männistö PT; Saarma M; Tuominen RK
    Exp Neurol; 2011 Mar; 228(1):99-108. PubMed ID: 21185834
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intrastriatally Infused Exogenous CDNF Is Endocytosed and Retrogradely Transported to Substantia Nigra.
    Mätlik K; Vihinen H; Bienemann A; Palgi J; Voutilainen MH; Booms S; Lindahl M; Jokitalo E; Saarma M; Huttunen HJ; Airavaara M; Arumäe U
    eNeuro; 2017; 4(1):. PubMed ID: 28275710
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evidence for an Additive Neurorestorative Effect of Simultaneously Administered CDNF and GDNF in Hemiparkinsonian Rats: Implications for Different Mechanism of Action.
    Voutilainen MH; De Lorenzo F; Stepanova P; Bäck S; Yu LY; Lindholm P; Pörsti E; Saarma M; Männistö PT; Tuominen RK
    eNeuro; 2017; 4(1):. PubMed ID: 28303260
    [TBL] [Abstract][Full Text] [Related]  

  • 6. AAV2-mediated striatum delivery of human CDNF prevents the deterioration of midbrain dopamine neurons in a 6-hydroxydopamine induced parkinsonian rat model.
    Ren X; Zhang T; Gong X; Hu G; Ding W; Wang X
    Exp Neurol; 2013 Oct; 248():148-56. PubMed ID: 23764500
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gene therapy with AAV2-CDNF provides functional benefits in a rat model of Parkinson's disease.
    Bäck S; Peränen J; Galli E; Pulkkila P; Lonka-Nevalaita L; Tamminen T; Voutilainen MH; Raasmaja A; Saarma M; Männistö PT; Tuominen RK
    Brain Behav; 2013 Mar; 3(2):75-88. PubMed ID: 23532969
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of cerebral dopamine neurotrophic factor on endogenous neural progenitor cell migration in a rat model of Parkinson's disease.
    Nasrolahi A; Mahmoudi J; Karimipour M; Akbarzadeh A; Sadigh-Eteghad S; Salehi R; Farajdokht F; Farhoudi M
    EXCLI J; 2019; 18():139-153. PubMed ID: 30956647
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination of CDNF and Deep Brain Stimulation Decreases Neurological Deficits in Late-stage Model Parkinson's Disease.
    Huotarinen A; Penttinen AM; Bäck S; Voutilainen MH; Julku U; Piepponen TP; Männistö PT; Saarma M; Tuominen R; Laakso A; Airavaara M
    Neuroscience; 2018 Mar; 374():250-263. PubMed ID: 29408408
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transient transfection of human CDNF gene reduces the 6-hydroxydopamine-induced neuroinflammation in the rat substantia nigra.
    Nadella R; Voutilainen MH; Saarma M; Gonzalez-Barrios JA; Leon-Chavez BA; Jiménez JM; Jiménez SH; Escobedo L; Martinez-Fong D
    J Neuroinflammation; 2014 Dec; 11():209. PubMed ID: 25511018
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic efficacy of AAV8-mediated intrastriatal delivery of human cerebral dopamine neurotrophic factor in 6-OHDA-induced parkinsonian rat models with different disease progression.
    Wang L; Wang Z; Zhu R; Bi J; Feng X; Liu W; Wu J; Zhang H; Wu H; Kong W; Yu B; Yu X
    PLoS One; 2017; 12(6):e0179476. PubMed ID: 28622392
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced neurotrophic distribution, cell signaling and neuroprotection following substantia nigral versus striatal delivery of AAV2-NRTN (CERE-120).
    Herzog CD; Brown L; Kruegel BR; Wilson A; Tansey MG; Gage FH; Johnson EM; Bartus RT
    Neurobiol Dis; 2013 Oct; 58():38-48. PubMed ID: 23631873
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparing neuroprotective effects of CDNF-expressing bone marrow derived mesenchymal stem cells via differing routes of administration utilizing an in vivo model of Parkinson's disease.
    Jiaming M; Niu C
    Neurol Sci; 2015 Feb; 36(2):281-7. PubMed ID: 25159816
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative Analysis of the Effects of Neurotrophic Factors CDNF and GDNF in a Nonhuman Primate Model of Parkinson's Disease.
    Garea-Rodríguez E; Eesmaa A; Lindholm P; Schlumbohm C; König J; Meller B; Krieglstein K; Helms G; Saarma M; Fuchs E
    PLoS One; 2016; 11(2):e0149776. PubMed ID: 26901822
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Key Subdomains of Cerebral Dopamine Neurotrophic Factor Regulate Its Protective Function in 6-Hydroxydopamine-Lesioned PC12 Cells.
    Liu H; Dong H; Wang C; Jia W; Wang G; Wang H; Zhong L; Gong L
    DNA Cell Biol; 2023 Nov; 42(11):680-688. PubMed ID: 37815547
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glial cell line-derived neurotrophic factor attenuates behavioural deficits and regulates nigrostriatal dopaminergic and peptidergic markers in 6-hydroxydopamine-lesioned adult rats: comparison of intraventricular and intranigral delivery.
    Lapchak PA; Miller PJ; Collins F; Jiao S
    Neuroscience; 1997 May; 78(1):61-72. PubMed ID: 9135089
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cerebral dopamine neurotrophic factor-deficiency leads to degeneration of enteric neurons and altered brain dopamine neuronal function in mice.
    Lindahl M; Chalazonitis A; Palm E; Pakarinen E; Danilova T; Pham TD; Setlik W; Rao M; Võikar V; Huotari J; Kopra J; Andressoo JO; Piepponen PT; Airavaara M; Panhelainen A; Gershon MD; Saarma M
    Neurobiol Dis; 2020 Feb; 134():104696. PubMed ID: 31783118
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protection and regeneration of nigral dopaminergic neurons by neurturin or GDNF in a partial lesion model of Parkinson's disease after administration into the striatum or the lateral ventricle.
    Rosenblad C; Kirik D; Devaux B; Moffat B; Phillips HS; Björklund A
    Eur J Neurosci; 1999 May; 11(5):1554-66. PubMed ID: 10215908
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Delivery of a GDNF gene into the substantia nigra after a progressive 6-OHDA lesion maintains functional nigrostriatal connections.
    Kozlowski DA; Connor B; Tillerson JL; Schallert T; Bohn MC
    Exp Neurol; 2000 Nov; 166(1):1-15. PubMed ID: 11031079
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modulating Microglia/Macrophage Activation by CDNF Promotes Transplantation of Fetal Ventral Mesencephalic Graft Survival and Function in a Hemiparkinsonian Rat Model.
    Tseng KY; Wu JS; Chen YH; Airavaara M; Cheng CY; Ma KH
    Biomedicines; 2022 Jun; 10(6):. PubMed ID: 35740467
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.